Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05376150 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
A Phase 2 study, sponsored by Xenon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT05376150 is a Phase 2 study that has completed, run by Xenon Pharmaceuticals. The registered enrollment target is 168 participants.
The verdict
NCT05376150, a Phase 2 study, has completed, sponsored by Xenon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
Interventions
- DRUG Placebo
- DRUG XEN1101 10 mg
- DRUG XEN1101 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2022-05-19 |
| Est. Completion | 2023-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05376150
The ClinicalTrials.gov registry entry for NCT05376150 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xenon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05376150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05376150 about?
NCT05376150 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder". This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
What is the current status of trial NCT05376150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2022-05-19. Estimated completion is 2023-10-16.
What interventions are being tested in trial NCT05376150?
The interventions under investigation include: Placebo (DRUG), XEN1101 10 mg (DRUG), XEN1101 20 mg (DRUG).
Who is sponsoring clinical trial NCT05376150?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.